Insights

DISCOVER

COMPANY

Survey

SURVEY

Consulting

COUNSULTING

Create New Account

Book discovery call

Next-Generation Sequencing Market: Current Analysis and Forecast (2021-2027)

Region:Global

Product Code:UMHE21308

Download Sample Report

Published On

July 2021

Total pages

162 Table of Content

Market Overview
Scope Of The Report
Product covered
Table Of Content
Research Methodology
FAQs

Download Sample Report

About the Report

Next-generation sequencing (NGS) is a technology used to determine the RNA or DNA sequence to study genetic variation associated with various types of diseases or other biological phenomena. This method was introduced for commercial use in 2005 and was initially known as massively-parallel sequencing as it enables the sequencing of several DNA strands at the same time. NGS provides the ideal throughput per run, and studies can be performed quickly and cost-effectively.

NGS is of extreme importance to medical practice as it provides a definitive diagnosis for many clinically heterogeneous diseases. Consequently, it enables a more precise disease prognosis and provides guidance towards the selection of the best therapeutic choices for the affected patients. Much of its current promise comes from its ability to examine the human genome at various stages, from chromosome to single-base changes.

The NGS market is growing exponentially on account of growing advancements in NGS technology, rising cancer incidences and increasing applications of NGS in various sectors. Further, the study of genomics is attracting attention from investors as well as from the public as it impacts the very core of lives and all living things around the globe. Completing the sequencing of the first human genome in 2003 was a key breakthrough that took over 10 years and cost approximately USD 3 billion. Since then, the sequencing speed of a genome has more than doubled, significantly outpacing Moore's Law. Today's high throughput sequencing machines process the human genome in a matter of hours at a cost approaching USD 1,000. These advancements have allowed researchers to analyze the genome in less time, greatly increasing the pace of scientific discovery.

Based on product/services, the market is fragmented into consumables, platforms, services, and bioinformatics. The consumables segment generated revenue of USD XX million in 2020. The market is expected to grow at a CAGR of XX% during the forecast period to reach a market valuation of USD XX million by 2027F owing to the increasing demand of the reagents and other consumables used for preparation of sample for sequencing of the genomes.

Based on technology, the market is bifurcated into SBS, SMRT, pyrosequencing, Ion semiconductor sequencing, nanopore sequencing and others. The SBS segment generated revenue of USD XX million in 2020. The market is expected to grow at a CAGR of XX% during the forecast period to reach a market valuation of USD XX million by 2027F as it one of the most widely adopted NGS technology globally.

Based on the application, the market is fragmented into biomarkers & cancer, diagnostics, drug discovery, personalized medicine, agriculture & animal research, and others. The biomarker segment dominated the market and generated revenue of USD XX million in 2020. However, personalized medicine is anticipated to grow at highest CAGR during the forecast period and reach USD XX million by 2027F.

The next-generation sequencing research and development and utilization are available at various centers including pharma companies, biotechnology companies, academic & government research institutes, clinical research, and others. The academic & government research institute segment is anticipated to dominate the market during the analyzed period and reach USD XX million by 2027F Owing to the growing number of collaborations among major key industry players and academic & government research institutes.

For a better understanding of the market adoption of the next-generation sequencing market, the market is analyzed based on its worldwide presence in the countries such as North America (United States and Canada), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), and Rest of World. North America constitutes a major market for the next-generation sequencing industry and generated revenue of USD XX million in 2020 owing to the increasing incidence of cancer and other diseases, rising healthcare spending, and increasing government initiatives in the region.

Some of the major players operating in the market include Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Bio-Rad Laboratories, F. Hoffmann-La Roche, BGI, Oxford Nanopore Technologies, PerkinElmer, Eurofins Scientific, etc. Several M&A's along with partnerships have been undertaken by these players to develop new and advanced NGS platforms.

Scope of the Report

Products

Next-generation sequencing (NGS) is a technology used to determine the RNA or DNA sequence to study genetic variation associated with various types of diseases or other biological phenomena.

Companies

Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Bio-Rad Laboratories, F. Hoffmann-La Roche, BGI, Oxford Nanopore Technologies, PerkinElmer, and Eurofins Scientific

1 MARKET INTRODUCTION

1.1 Market Definitions

1.2 Objective of the Study

1.3 Limitation

1.4 Stake Holders

1.5 Currency Used in Report

1.6 Scope of the Global Next-generation Sequencing Market Study

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1 Research Methodology for the Global Next-generation Sequencing Market

2.1.1 Main Objective of the Global Next-generation Sequencing Market

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 COVID-19 IMPACT

6 GLOBAL NEXT-GENERATION SEQUENCING MARKET REVENUE

7 MARKET INSIGHTS BY PRODUCT/SERVICES

7.1 Consumables

7.2 Platforms

7.3 Services

7.4 Bioinformatics

8 MARKET INSIGHTS BY TECHNOLOGY

8.1 SBS

8.2 SMRT

8.3 Pyrosequencing

8.4 Ion Semiconductor Sequencing

8.5 Nanopore Sequencing

8.6 Others

9 MARKET INSIGHTS BY APPLICATION

9.1 Biomarkers & Cancer

9.2 Diagnostics

9.3 Drug Discovery

9.4 Personalized Medicine

9.5 Agriculture & Animal Research

9.6 Others

10 MARKET INSIGHTS BY END-USERS

10.1 Pharma Companies

10.2 Biotechnology Companies

10.3 Academic & Government Research Institutes

10.4 Clinical Research

10.5 Others

11 MARKET INSIGHTS BY REGION

11.1 NORTH AMERICA NEXT-GENERATION SEQUENCING MARKET

11.1.1 United States

11.1.2 Canada

11.1.3 Rest of North America

11.2 EUROPE NEXT-GENERATION SEQUENCING MARKET

11.2.1 Germany

11.2.2 France

11.2.3 United Kingdom

11.2.4 Spain

11.2.5 Italy

11.2.6 Rest of Europe

11.3 ASIA PACIFIC NEXT-GENERATION SEQUENCING MARKET

11.3.1 China

11.3.2 Japan

11.3.3 India

11.3.4 Australia

11.3.5 Rest of Asia Pacific

11.4 REST OF THE WORLD NEXT-GENERATION SEQUENCING MARKET

12 NEXT-GENERATION SEQUENCING MARKET DYNAMICS

12.1 Market Drivers

12.2 Market Challenges

12.3 Impact Analysis

13 NEXT-GENERATION SEQUENCING MARKET OPPORTUNITIES

14 NEXT-GENERATION SEQUENCING MARKET TRENDS & INSIGHTS

15 LEGAL & REGULATORY FRAMEWORK

16 DEMAND AND SUPPLY SIDE ANALYSIS

16.1 Demand Side Analysis

16.2 Supply Side Analysis

16.2.1 Top Product Launches

16.2.2 Top Business Partnerships

16.2.3 Top Merger & Acquisitions

17 VALUE CHAIN ANALYSIS

18 COMPETITIVE SCENARIO

18.1 Porter's Five forces analysis

18.1.1 Bargaining power of Supplier

18.1.2 Bargaining power of Buyer

18.1.3 Industry Rivalry

18.1.4 Availability of Substitute

18.1.5 Threat of new Entrants

19 COMPANY PROFILED

19.1 Bio-rad Laboratories

19.1.1 Key Facts

19.1.2 Business Description

19.1.3 Key Product/Services Offerings

19.1.4 Growth Strategy

19.1.5 SWOT Analysis

19.1.6 Key Financials

19.1.6.1 Revenue Split

19.1.6.2 Financial Overview of Bio-rad Laboratories

19.1.7 Recent Developments

19.1.7.1 Product Launch

19.1.7.2 Partnerships

19.1.7.3 Business Expansion and Investments

19.1.7.4 Merger and Acquisition

19.2 Agilent Technologies

19.3 Illumina, Inc.

19.4 Thermo Fisher Scientific

19.5 F. Hoffmann-La Roche

19.6 Oxford Nanopore Technologies

19.7 Qiagen

19.8 BGI

19.9 PerkinElmer

19.10 Eurofins Scientific

20 DISCLAIMER

Research Methodology

Why Buy From Us?

Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository

150+ Consulting project a year

100+ Analysts

8000+ Client Queries in 2022